Mary F. Mulcahy
Northwestern University
285 Papers
1.8K Citations
Mary F. Mulcahy is an academic researcher from Northwestern University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 74, co-authored 253 publications. Previous affiliations of Mary F. Mulcahy include City of Hope National Medical Center & University of Chicago.
Chat about Author
Papers
Tesetaxel, a novel oral taxane, as second-line therapy for advanced gastroesophageal cancer: Activity in a dose-ranging study.
TL;DR: It is confirmed that tesetaxel is active against gastroesophageal cancers in the 2nd-line setting using the weight-based Q3 week regimen using the structurally novel orally active taxane.
6
Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704.
Danielle S. Bitterman,Kathryn Winter,Theodore S. Hong,Charles S. Fuchs,William F. Regine,Ross A. Abrams,Howard Safran,John P. Hoffman,Al B. Benson,Timothy Kasunic,Mary F. Mulcahy,James F. Strauss,Thomas A. DiPetrillo,Philip J. Stella,Yuhchyau Chen,John P. Plastaras,Christopher H. Crane +16 more
TL;DR: DM and insulin use were not associated with OS or DFS in patients with pancreatic cancer in this study, and race, nodal involvement, and increased CA19-9 were significant predictors of outcomes.
5
Abstract No. 274: Development of the VX2 Pancreatic Cancer Model in Rabbits: A Platform to Test Future Interventional Radiology Therapies
Aaron C. Eifler,Robert J. Lewandowski,J. Chung,Sumeet Virmani,Dingxin Wang,Richard Tang,Barbara Szolc-Kowalska,Gayle E. Woloschak,Mary F. Mulcahy,Robert K. Ryu,Riad Salem,Andrew C. Larson,Eric C. Cheon,Matthew J. Strouch,D. Zarlengo,David J. Bentrem,Reed A. Omary +16 more
5
Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC).
Robin Katie Kelley,Halla Sayed Nimeiri,Maxwell T. Vergo,K. Chia,Mary F. Mulcahy,Emily K. Bergsland,Andrew H. Ko,Pamela N. Munster,Al B. Benson,Alan P. Venook +9 more
TL;DR: A phase I trial of mTOR-I TEM plus SOR to determine safety, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) in pts with HCC found tx-limiting, class-related AE occurred at DL1 of this double-biologic regimen.
5
The Safety and Tolerability of Veliparib (V) plus Capecitabine (C) and Radiation (RT) in Subjects with Locally Advanced Rectal Cancer (LARC): Results of a Phase 1b Study
Brian G. Czito,Mary F. Mulcahy,W. Schelman,Houman Vaghefi,J. Gayle,Angela DeLuca,Hao Xiong,Wijith Munasinghe,D. Matthew,Kyle D. Holen,Michael Michael +10 more
5